IBUTILIDE FUMARATE

Post-LOE

ibutilide fumarate

Viatris (2)

ANDAINJECTIONINJECTABLE

Approved

Jan 2010

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

IBUTILIDE FUMARATE (ibutilide fumarate) by Viatris (2) is mechanism of action ibutilide fumarate injection prolongs action potential duration in isolated adult cardiac myocytes and increases both atrial and ventricular refractoriness in vivo, i. Approved for atrial fibrillation. First approved in 2010.

Drug data last refreshed 18h ago

Mechanism of Action

Mechanism of Action Ibutilide fumarate injection prolongs action potential duration in isolated adult cardiac myocytes and increases both atrial and ventricular refractoriness in vivo, i.e., class III electrophysiologic effects. Voltage clamp studies indicate that ibutilide fumarate injection, at…

Indications (1)

atrial fibrillation

Worked on IBUTILIDE FUMARATE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.